Every Form 4 that Krystal Biotech, Inc. (KRYS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow KRYS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KRYS filings page.
Krystal Biotech, Inc. (KRYS) reported that director Dino A. Rossi received new equity awards on September 14, 2026. He was granted options to purchase 1,187 shares of common stock at an exercise price of $340.03 per share, expiring on September 13, 2036, which vest in full on September 14, 2027, subject to continued service on the Board and earlier vesting conditions under the company's Non-Employee Director Compensation Policy. He also received 471 restricted stock units, each representing a contingent right to one share of common stock, which vest in full on September 14, 2027 under the same service and policy conditions.
Krystal Biotech, Inc. (symbol: KRYS) is the issuer of record for a Form 4 filing submitted to the SEC. Sutherland Everett Rand reported acquisition or exercise transactions in this Form 4 filing.
Krystal Biotech, Inc. (KRYS) reported that director Everett Rand Sutherland received equity awards on September 14, 2026. He was granted 1,187 stock options to buy common stock at $340.03 per share, vesting in full on September 14, 2027, and 471 restricted stock units, also vesting in full on that date, in each case subject to continued Board service and earlier vesting conditions under the company’s Non-Employee Director Compensation Policy.
Krystal Biotech, Inc. (symbol: KRYS) is the issuer of record for a Form 4 filing submitted to the SEC. Mazzacco Catherine reported acquisition or exercise transactions in this Form 4 filing.
Krystal Biotech, Inc. (KRYS) reported that director Catherine Mazzacco received equity awards on September 14, 2026. She was granted 1,187 stock options to buy common stock at $340.03 per share, expiring on September 13, 2036, and 471 restricted stock units. Both awards vest in full on September 14, 2027, subject to her continued service on the board and potential earlier vesting under the company’s Non-Employee Director Compensation Policy. No Rule 10b5-1 trading plan is reported for these awards.
Krystal Biotech, Inc. (symbol: KRYS) is the issuer of record for a Form 4 filing submitted to the SEC. Mason Christopher reported acquisition or exercise transactions in this Form 4 filing.
Krystal Biotech, Inc. director Christopher Mason received equity awards in the form of stock options and restricted stock units. On September 14, 2026 he was granted 1,187 stock options to buy common stock at $340.03 per share, expiring September 13, 2036, and 471 restricted stock units, each representing one share of common stock. Both the options and RSUs vest in full on September 14, 2027, subject to his continued service on the Board of Directors and potential earlier vesting under the company’s Non-Employee Director Compensation Policy. No Rule 10b5-1 trading plan is reported.
Krystal Biotech, Inc. (KRYS) reported that director Daniel Janney received equity awards on September 14, 2026. He was granted 1,187 stock options with an exercise price of $340.03 per share, expiring on September 13, 2036, and 471 restricted stock units. Both the options and RSUs vest in full on September 14, 2027, subject to Mr. Janney’s continued service on the board and earlier vesting conditions described in the company’s Non-Employee Director Compensation Policy. No Rule 10b5-1 trading plan is reported.
Krystal Biotech, Inc. (KRYS) reported that director Julian S. Gangolli received equity awards on September 14, 2026. He was granted 1,187 stock options with an exercise price of $340.03 per share, expiring on September 13, 2036, and 471 restricted stock units. Both the options and RSUs vest in full on September 14, 2027, subject to his continued service on the Board and earlier vesting conditions under the company’s Non-Employee Director Compensation Policy.
Krystal Biotech, Inc. (KRYS) insider Suma Krishnan, a director, President of R&D, and ten percent owner, reported open-market sales of 25,000 shares of common stock on September 4, 2026. The sales were executed in multiple trades at prices within ranges from $353.98 to $366.91 per share and were made under a Rule 10b5-1 trading plan adopted on September 4, 2025, which has now reached its maximum share amount and terminated. Following these transactions, Krishnan continues to hold shares indirectly through several family trusts, including 90,000 shares held by the Krishnan Spousal Trust, 51,010 shares held by the Suma Mani Krishnan Trust, and 50,000 shares held by the Krishnan Family Trust.
Krystal Biotech, Inc. (KRYS) reports that President and CEO, director, and more-than-10% owner Krishnan Krish S sold 25,000 shares of common stock on September 4, 2026 in multiple open-market transactions around the mid-$350s per share, under a Rule 10b5-1 trading plan adopted September 4, 2025 that has now reached its maximum and terminated. He continues to hold shares indirectly through family trusts, including 90,000, 77,710, and 50,000 shares, respectively.
Krystal Biotech, Inc. director Dino A. Rossi reported dispositions of Common Stock on August 14, 2026. He made a bona fide gift of 3,691 shares to a charitable donor-advised fund and sold 25,000 shares in multiple open-market transactions at weighted average prices ranging from $325.5985 to $333.23 per share, as detailed in trade-level footnotes.
Krystal Biotech EVP and General Counsel Thomas John Charles reported an exercise-and-sale transaction in company stock. He exercised stock options to acquire 1,000 shares of common stock at $179.25 per share and then sold 1,000 shares in an open-market transaction at $347.27 per share, leaving him with no directly held common shares. Following the derivative transaction, he continued to hold 6,500 stock options expiring on February 27, 2035. According to a footnote, both the acquisition and sale were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 23, 2026, and that plan has now fully completed and terminated.
Krystal Biotech, Inc. director and President, R&D Suma Krishnan reported open-market sales of 25,000 shares of common stock. The transactions took place on June 4, 2026 in multiple trades at prices generally ranging from about $300.75 to $311.65 per share.
The filing states that these sales were made under a pre-established Rule 10b5-1 trading plan adopted on September 4, 2025, which began on December 4, 2025 and is scheduled to run until December 4, 2026 unless completed earlier. Krishnan also reports indirect ownership of 50,000 shares through the Krishnan Family Trust and 90,000 shares through the Krishnan Spousal Trust.
Krystal Biotech, Inc.’s President and CEO Krish S. Krishnan reported open-market sales of 25,000 shares of common stock on June 4, 2026. The shares were sold in multiple trades with reported weighted average prices such as $312.23 and $300.75 per share.
The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025, which began on December 4, 2025 and is scheduled to terminate on December 4, 2026 or earlier under its terms. After these transactions, Krishnan directly holds 1,450,253 shares and indirectly holds 90,000 shares through the SMK Trust FBO KSK and 50,000 shares through the Krishnan Family Trust, where he shares voting and investment power. Shares directly owned by his spouse are reported separately and are disclaimed except for any pecuniary interest.
Krystal Biotech, Inc. executive vice president and general counsel Thomas John Charles sold 642 shares of common stock in an open-market transaction. The shares were sold at an average price of $302.03 per share on May 26, 2026, and his directly held common stock position reported in this filing is now zero shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 23, 2026, which is scheduled to run through December 31, 2026 unless it terminates earlier under its terms.
Krystal Biotech President of R&D and director Suma Krishnan sold 25,000 shares of the company’s common stock on March 4, 2026 in open-market trades under a pre-arranged Rule 10b5-1 trading plan. The reported sales occurred at prices between $256.68 and $266.93 per share.
After these transactions, she directly held 1,403,155 shares of Krystal Biotech common stock. She also had indirect ownership of 90,000 shares through SMK Trust and 50,000 shares through the Krishnan Family Trust, where she and her spouse are joint beneficial owners with joint voting and investment control.
Krystal Biotech, Inc. reported that President and CEO Krishnan Krish sold 25,000 shares of common stock on March 4, 2026 in multiple open‑market transactions. The weighted average sale prices disclosed in the table range from about $257.31 to $266.56 per share.
The footnotes state these sales were made under a pre‑arranged Rule 10b5‑1 trading plan adopted on September 4, 2025, which began on December 4, 2025 and is scheduled to terminate on December 4, 2026 or earlier under its terms. After these sales, Krish directly owned 1,475,253 shares and also had indirect holdings of 90,000 and 50,000 shares through spousal and family trusts.
Krystal Biotech, Inc. Chief Accounting Officer Kathryn Romano reported a mix of stock sales, vesting, and new equity awards. On March 2, 2026, she completed an open-market sale of 750 shares of common stock at $267.60 per share under a pre-arranged Rule 10b5-1 trading plan, leaving 22,366 common shares held directly.
On February 27, 2026, 7,500 performance stock units vested after meeting 2024 performance goals, and 550 restricted stock units vested from a 2025 grant, both converting into common shares. To cover tax withholding on these vestings, 3,262 and 240 common shares, respectively, were surrendered to the company at a reference price of $275.64 per share.
Also on February 27, Romano received new equity incentives: a stock option for 13,575 shares and a new grant of 5,442 restricted stock units, each vesting in four equal annual installments beginning February 27, 2027.
Krystal Biotech President of R&D Suma Krishnan reported multiple equity compensation events and related tax withholdings. On February 27, 2026, 22,500 performance stock units vested after meeting 2024 performance goals, and 4,000 restricted stock units vested from a 2025 grant. Shares were automatically surrendered to the company to cover taxes at a share price of $275.64.
New awards on the same date included 18,100 stock options vesting annually from February 27, 2027, 7,256 time‑based RSUs vesting over four years starting in 2027, and 43,536 performance stock units tied to multi‑year performance criteria through 2029. Additional vested RSUs and PSUs, related tax‑withholding dispositions, and resulting common stock were reported as indirectly owned through the spouse and through family trusts.
Krystal Biotech, Inc.’s President and CEO, Krish S. Krishnan, reported multiple equity compensation events on February 27, 2026. Previously granted restricted stock units and performance stock units vested, converting into shares of common stock for both him and his spouse, Suma M. Krishnan.
Related shares of common stock were surrendered to the company to cover tax withholding obligations at a price of $275.64 per share, classified as tax-withholding dispositions rather than open-market sales. Krishnan also received a new grant of stock options for 45,249 shares and 18,140 restricted stock units, both vesting in equal annual installments beginning on February 27, 2027, subject to continued service.
Additional indirect holdings are reported through Krishnan’s spouse and the Krishnan Family Trust, where he and his spouse share joint voting and investment control.
Krystal Biotech director-linked entity sells shares under trading plan
Alta Bioequities, L.P., an entity associated with Krystal Biotech director Daniel Janney, sold a total of 11,803 shares of the company’s common stock in two open-market transactions on February 27, 2026, at weighted average prices of $275.4487 and $276.1665 per share.
The sales were executed under a pre-established Rule 10b5-1 trading plan adopted on November 25, 2025, which is scheduled to terminate on November 5, 2026, subject to early termination. Alta Bioequities, L.P. continued to hold 73,293 shares after these transactions.
Krystal Biotech director Daniel Janney reported option exercises and share sales in Krystal Biotech, Inc. common stock. On February 24, 2026, he exercised stock options covering 37,895 shares and received the same number of common shares, then sold those shares in multiple open-market transactions.
On February 24 and 26, 2026, additional open-market sales were reported in accounts indirectly holding shares for Alta Bioequities, L.P., which is managed by an affiliated general partner. The filing notes that Janney’s option exercise and sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 25, 2025. After these trades, 85,096 shares were held indirectly through Alta Bioequities, L.P., while no shares were held directly.
Krystal Biotech, Inc. director Dino A. Rossi reported option exercises and related share sales. On February 19, 2026, he exercised stock options for 18,950 shares of common stock at $8.79 per share. The options vested ratably over four years beginning on June 1, 2018. On the same date, he sold 8,116 shares at $260.4858 and 10,834 shares at $262.10 in open-market transactions, totaling 18,950 shares sold. After these trades, he directly owned 78,691 shares of Krystal Biotech common stock.
Krystal Biotech Chief Accounting Officer Kathryn Romano reported exercising stock options for 12,500 shares of common stock at an exercise price of $63.55 per share on February 9, 2026, then selling the same 12,500 shares in multiple open‑market trades at prices between $270.010 and $277.88 per share. Following these sales, she directly owned 18,568 shares of Krystal Biotech common stock.
The option exercise, share sales, and a 750‑share bona fide gift to a charitable donor‑advised fund were carried out under a pre‑arranged Rule 10b5‑1 trading plan that began on November 6, 2025 and is scheduled to run through August 31, 2026, subject to earlier termination under its terms.